UK Pharmacies Test E-Cigarettes as Smoking Cessation Aid in Pilot Program

Nov.20.2024
UK Pharmacies Test E-Cigarettes as Smoking Cessation Aid in Pilot Program
A pilot program in Kent uses e-cigarettes for smoking cessation, aligning with the government's 2030 smoke-free target, as varenicline returns to NHS prescriptions after safety concerns.

The Community Pharmacy of England (CPE) announced that community pharmacies in Maidstone, Kent, are participating in a pilot program using e-cigarettes as a smoking cessation aid, according to The Pharmaceutical Journal on November 19.

 

Seven pharmacies are offering locally commissioned services, where smoking cessation advisors will provide patients with a voucher for a starter kit and up to a four-week supply of vape liquid. 

 

Patients can also access six other nicotine replacement products, though the service recommends vaping as a short-term aid for quitting smoking.

 

"The pilot is in response to the government's ambition for England to be smoke-free by 2030 and follows reflection by the Medway Public Health Team that, to achieve this, 50% of smokers will need to undertake a quit attempt every year," CPE said.

 

A Cochrane review published in September 2023 found that e-cigarettes, varenicline, and cytisine were the most effective aids for quitting smoking for six months or longer, with similar effectiveness among the three.

 

The review analyzed data from over 150,000 participants and showed that 10–19% of individuals quit smoking with e-cigarettes, 12–16% with varenicline, and 10–18% with cytisine.

 

"Community pharmacies already play a significant role in supporting people to stop smoking, but we believe more value could be created by the sector at a population health level as well as benefits to individuals, in line with the government's desire to achieve a smoke-free country and to reduce the use of vapes," the director of NHS services at the CPE, Alastair Buxton, said.

 

"Stopping smoking is not easy, but research shows that e-cigarettes are nearly twice as effective as nicotine replacement therapies, such as patches and gum, when used in a Stop Smoking Service setting," said Caroline Cerny, deputy chief executive at Action on Smoking and Health.

 

In November 2024, NHS England announced the reintroduction of varenicline for NHS patients, three years after its withdrawal due to high levels of N-nitroso-varenicline, a probable carcinogen. Previously a first-line smoking cessation treatment, varenicline was recalled by Pfizer in October 2021 over these safety concerns.

 

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26